Weight-loss drugs and cancer outcomes

New research suggests popular GLP-1 weight-loss medications, such as semaglutide-based drugs, may influence cancer risk or outcomes in ways scientists did not initially anticipate. Researchers are examining potential links between the drugs' effects on weight, metabolism, and inflammation and their impact on certain cancers, though findings remain preliminary. Experts caution that more study is needed to confirm the connection and understand whether the drugs help or complicate cancer treatment and prevention.